Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
ApexOnco Front Page
Recent articles
But now it must show that varseta-M can move into a registrational trial.
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
New data with pasritamig plus docetaxel support a recent pivotal start.
The first fruit of a long-standing deal with Roche enters phase 1 in March.
An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.
But biomarker enrichment and toxicity remain key for FX-909.
